Paxlovid Users May Face Rebound SARS-CoV-2
The U.S. Centers for Disease Control and Prevention (CDC) has admitted that COVID-19 patients may experience a rebound SARS-CoV-2 infection after taking Pfizer’s antiviral drug, Paxlovid. Evidence has shown that patients, including those who have gotten COVID shots and been boosted, may suffer a reoccurrence of COVID two to eight days after completing a five-day […]
Moderna CEO Was Paid $18.2 Million in 2021
As COVID-19 vaccine sales continue to soar, Moderna Chief Executive Stephane Bancel’s total personal financial compensation increased by 41 percent in 2021, reaching $18.2 million. The company’s total revenue rose 2,200 percent in 2021, jumping from $803 million to $18.5 billion.1 2 Moderna partnered with the National Institute of Allergy and Infectious Diseases (NIAID), headed […]
Pfizer CEO Received $24.3 Million in Total Compensation for 2021
Pfizer CEO Albert Bourla, who recently announced that a fourth COVID-19 vaccine dose will be necessary for everyone who has already gotten three doses, was awarded $24.3 million in personal financial compensation in 2021. In addition to his $1.69 million salary, which increased by 15 percent, Bourla took home a cash incentive of $8 million, […]
The Purge: Call Me Ishmael
For the last 27 years, I have been a professor at Boston College, teaching a mix of literature and writing courses to thousands of students. Then along came the booster mandates. When the initial vaccines came out, my wife and I received ours. We had strong reservations about the mRNA vaccines and had decided we […]
Harvard Study’s Goal: Identifying Messages That ‘Break Through’ to Vaccine Skeptics
“If only there were a message that could break through skepticism and persuade unvaccinated people to get their shots. What a world that would be. But over the past year, this really did happen,” reads a February 2022 Vox article1 that continues on to describe a Harvard Business School publication2 which offers new evidence on […]
Sales of Pfizer COVID-19 Biologic for 2021-2022 May Near $70 Billion
Based on better than expected sales of its experimental messenger RNA (mRNA) BNT162b2 COVID-19 biologic, New York-based pharmaceutical company Pfizer, Inc. last summer revised projected sales of its experimental drug, also known as “Comirnaty,” from $26 billion to $33.5 billion in 2021. Characterizing second-quarter sales of BNT162b2 as “remarkable,” Pfizer’s chief executive officer (CEO) Albert […]
